MRK vs QCOM: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and QUALCOMM Incorporated — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-20.
Merck & Co., Inc. · Healthcare
$114.27
+3.3% upside to fair value
Grade C
High Quality
VS
QUALCOMM Incorporated · Technology
$134.47
+45.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
QCOM has more upside to fair value
(+45.0%).
MRK trades at a lower forward P/E
(22.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
QCOM |
| Current Price |
$114.27 |
$134.47 |
| Fair Value Estimate |
$118.00 |
$194.98 |
| Upside to Fair Value |
+3.3%
|
+45.0%
|
| Market Cap |
$282.2B |
$143.6B |
| Forward P/E |
22.4x
|
26.8x
|
| EV / EBITDA |
13.5x
|
—
|
| Price / Sales |
4.3x
|
3.2x
|
| Price / FCF |
20.2x
|
11.1x
|
| Revenue Growth YoY |
+5.0%
|
+8.7%
|
| Gross Margin |
81.9%
|
55.1%
|
| Operating Margin |
27.5%
|
27.1%
|
| Return on Equity |
5.6%
|
21.6%
|
| Dividend Yield |
2.91% |
— |
| FCF Yield |
4.95%
|
9.0%
|
| Analyst Consensus |
Overweight
|
Hold
|
Investment Thesis
Merck delivered a clean Q1 2026 operational beat on April 30, with revenue of 16.3 billion dollars growing 5 percent year over year and Keytruda sales rising 12 percent to 8.0 billion dollars. The reported loss of 1.28 dollars per share, though better than the negative 1.47 dollar consensus estimate, reflected a 3.62 dollar per share IPR and D charge tied to the Cidara Therapeutics acquisition an…
Qualcomm Incorporated is a leading semiconductor company specializing in wireless chipsets and IP licensing, with dominant positions in 5G modems via QCT (87% of revenue) and steady QTL royalties. The business excels through a vast patent moat, diversification into automotive and IoT, and robust growth (revenue +13% YoY to $44B in FY2025), but faces risks from Apple modem shifts and China exposur…
Accumulation Zones
| Metric |
MRK |
QCOM |
| Zone Low |
$88.50 |
$146.23 |
| Zone High |
$100.30 |
$165.73 |
| In Buy Zone? |
No
|
Yes
|